Montreal, Canada
DalCor Pharmaceuticals, founded in 2015 and headquartered in Canada, is making notable strides in the Health Care and Pharmaceutical industries. Their endeavor, epitomized by the slogan “Pioneering Pharmacogenetic Precision Medicine for Cardiovascular Disease,” underscores their focus on precision medicine targeting cardiovascular health.
The company's flagship development, dalcetrapib, is designed to improve cardiovascular outcomes by reducing the occurrence of both fatal and non-fatal myocardial infarctions in genetically specific patients following an acute coronary episode.
In its latest financial move, DalCor Pharmaceuticals secured an $80.00M Series D investment on 13 September 2023. This funding round was backed by prominent investors like CTI Life Sciences Fund, Investissement Québec, Andes, T&B Pharma, Fonds de solidarité FTQ, and Ministère de l’Economie, des Finances et du Budget, indicating strong investor confidence and support in their mission.
